Related Experiment Videos
Effect of nadolol on plasma lipids in hyperthyroidism
M D Littley1, J C Kingswood, R John
1University of Wales College of Medicine, Llandough Hospital, Penarth, S. Glam., Wales, United Kingdom.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|June 1, 1989
Summary
Nadolol treatment in hyperthyroid patients significantly increased triglycerides compared to placebo. This beta-blocker impacts lipid profiles during early hyperthyroid management.
Area of Science:
- Endocrinology
- Cardiovascular Pharmacology
Background:
- Hyperthyroidism significantly alters lipid metabolism, often leading to lower cholesterol levels.
- Beta-blockers like Nadolol are used to manage hyperthyroid symptoms.
Purpose of the Study:
- To investigate the effects of Nadolol on lipid subfractions in hyperthyroid patients.
- To compare lipid profile changes between Nadolol and placebo groups during early hyperthyroid management.
Main Methods:
- A six-week randomized, double-blind, placebo-controlled trial involving 23 hyperthyroid patients.
- Carbimazole was administered to both groups from weeks 2 to 6.
- Lipid subfractions, including total cholesterol, LDL, HDL, and triglycerides, were measured.
Main Results:
- Nadolol treatment led to significant increases in total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides.
- The rise in triglycerides was significantly greater in the Nadolol group compared to the placebo group.
- No significant effect of Nadolol on peripheral T4 to T3 monodeiodination was observed.
Conclusions:
- Nadolol significantly impacts lipid subfractions, particularly triglycerides, in hyperthyroid patients.
- The observed lipid changes suggest Nadolol may influence lipid metabolism during the early stages of hyperthyroidism treatment.